Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765 on ClinicalTrials.gov · last registry update 2026-08-14
Recruiting now, toward 250 participants. Due to report 29 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in Apnea-hypopnea Index (AHI) from baseline at Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 250
- Started
- 2025-11-25
- Primary completion
- 2027-09-29 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Apnea-hypopnea Index (AHI) from baseline at Week 52
Conditions studied
Obstructive Sleep Apnea
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.